Navigation Links
Jefferson is first academic medical center to offer FDA-approved BRAF mutation for melanoma patients

PHILADELPHIAThomas Jefferson University Hospital is the first academic medical center in the United States to offer the recently-approved U.S. Food and Drug Administration (FDA) diagnostic tool that tests melanoma patients for the BRAF mutation (which occurs in about half of all cases) and ultimately determines if they'll benefit from a new, potentially life-saving drug.

In August, the FDA approved the oral drug vemurafenib to treat patients whose melanoma cells have the BRAF V600E mutation, as determined by the companion diagnostic test, after clinical trials showed that the drug significantly extended survival in metastatic melanoma patients with the mutation.

Jefferson's clinical laboratories have officially begun utilizing the FDA-approved test to help determine melanoma patients' status and a subsequent and immediate treatment plan. According to Roche Diagnostics, its tool has improved sensitivity, accuracy and speed compared to other commonly used detection methods.

"It is very important to us at Jefferson to offer patients a personalized approach, starting with the pathology of their diseases all the way through their treatment," says Stephen C. Peiper, M.D., Peter A. Herbut Professor and Chair of the Department of Pathology, Anatomy and Cell Biology at Thomas Jefferson University.

"Melanoma is a deadly skin cancer, and this FDA-approved diagnostic tool plays a pivotal role in our approach to it. The BRAF mutation test will allow us to quickly and accurately identify patients here at the hospital who will respond positively to this new treatment," he adds.

An estimated 50 percent of patients with melanoma have this type of mutation.

The FDA approval of vemurafenib is based on results from two clinical studies in people with BRAF V600E mutation-positive, inoperable or metastatic melanoma as determined by the mutation test.

The risk of death was reduced by 56 percent for people who received vemurafenib compared to those who received chemotherapy. People who received vemurafenib also had a 74 percent reduced risk of the disease getting worse or dying compared to those who received chemotherapy. The confirmed investigator-assessed response rate (those who experienced tumor shrinkage) in people who received vemurafenib was 48.4 percent compared to 5.5 percent for those who received chemotherapy.

Vemurafenib is a BRAF inhibitor that blocks the function of the V600E-mutated BRAF protein and should be used only in people whose inoperable or metastatic melanoma carries a mutation.


Contact: Steve Graff
Thomas Jefferson University

Related medicine news :

1. Thomas Jefferson University Hospital cuts Whipple procedure wound infections in half with new measures
2. Jefferson physician named an Educator of the Year by the Assocociation of Residents in Radiation Oncology
3. Thomas Jefferson University Hospital adopts new imaging agent to improve detection of bladder cancer
4. Thomas Jefferson University and hospitals tasked to find new radiation drugs
5. FDA approval of brain aneurysm device gives Jefferson neurosurgeons another life-saving tool
6. Jefferson doctors strengthen case for high-dose radiotherapy technique after radical prostatectomy
7. Kimmel Cancer Center at Jefferson breast cancer symposium features latest in research, treatment
8. Jefferson clinical trial: Can a cholesterol drug prevent colon cancer?
9. Thomas Jefferson University professor elected AAAS Fellow
10. Jefferson study determines bone marrow stromal stem cells may aid in stroke recovery
11. CancerCare names Jefferson professor Physician of the Year
Post Your Comments:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 2016 , ... A recent article published June 14 on E ... goes on to state that individuals are now more comfortable seeking to undergo not ... as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
Breaking Medicine Technology: